(Boursier.com) — Neovacs a preclinical-stage biopharmaceutical company developing new therapies for inflammatory and autoimmune diseases, announces that new results have been presented on candidate vaccine development projects in the field of asthma treatment.
These results gave rise to an oral presentation and a poster during the annual Congress of the European Molecular Biology Organization (EMBO / European Molecular and Biology Organization) entitled: Workshop Antibodies and complement: effector functions, therapies and technologies.
Title of oral presentation: Anti-IgE vaccination for the treatment of allergic disease.
Poster title: Dual vaccination against human IL-4 and IL 13 protect against key features of allergic asthma in human IL-4/IL-13IL-4R alpha knock-in mice.
The work presented bears witness to the significant advances in these two programs (anti-IgE project and IL-4 and IL-13 project) for the treatment of asthma. In particular, the poster echoes the results recently published in Allergy, a peer-reviewed journal, available since March 2023 online and since July 7 in the classic version. This article is available at the following link:
https://pubmed.ncbi.nlm.nih.gov/36799426/
©2023 Boursier.com